Cargando…
Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension
Hypertension (HTN) involves genetic variability in the renin-angiotensin system and characterizing this variability will help advance precision antihypertensive treatments. We previously reported that angiotensinogen (AGT) mRNA is endogenously bound by mir-122-5p and that rs699 A>G significantly...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104131/ https://www.ncbi.nlm.nih.gov/pubmed/37066278 http://dx.doi.org/10.1101/2023.04.07.536073 |
_version_ | 1785025976819777536 |
---|---|
author | Powell, Nicholas R. Shugg, Tyler Leighty, Jacob Martin, Matthew Kreutz, Rolf P. Eadon, Michael T. Lai, Dongbing Lu, Tao Skaar, Todd C. |
author_facet | Powell, Nicholas R. Shugg, Tyler Leighty, Jacob Martin, Matthew Kreutz, Rolf P. Eadon, Michael T. Lai, Dongbing Lu, Tao Skaar, Todd C. |
author_sort | Powell, Nicholas R. |
collection | PubMed |
description | Hypertension (HTN) involves genetic variability in the renin-angiotensin system and characterizing this variability will help advance precision antihypertensive treatments. We previously reported that angiotensinogen (AGT) mRNA is endogenously bound by mir-122-5p and that rs699 A>G significantly decreases reporter mRNA in the functional mirSNP assay PASSPORT-seq. The AGT promoter variant rs5051 C>T is in linkage disequilibrium (LD) with rs699 A>G and increases AGT transcription. We hypothesized that the increased AGT by rs5051 C>T counterbalances AGT decrease by rs699 A>G, and when these variants occur independently, would translate to HTN-related phenotypes. The independent effect of each of these variants is understudied due to their LD, therefore, we used in silico, in vitro, in vivo, and retrospective clinical and biobank analyses to assess HTN and AGT expression phenotypes where rs699 A>G occurs independently from rs5051 C>T. In silico, rs699 A>G is predicted to increase mir-122-5p binding strength by 3%. Mir-eCLIP assay results show that rs699 is 40-45 nucleotides from the strongest microRNA binding site in the AGT mRNA. Unexpectedly, rs699 A>G increases AGT mRNA in a plasmid cDNA HepG2 expression model. GTEx and UK Biobank analyses demonstrate that liver AGT expression and HTN phenotypes were not different when rs699 A>G occurs independently from rs5051 C>T, allowing us to reject the original hypothesis. However, both GTEx and our in vitro experiments suggest rs699 A>G confers cell-type specific effects on AGT mRNA abundance. We found that rs5051 C>T and rs699 A>G significantly associate with systolic blood pressure in Black participants in the UK Biobank, demonstrating a 4-fold larger effect than in White participants. Further studies are warranted to determine if the altered antihypertensive response in Black individuals might be due to rs5051 C>T or rs699 A>G. Studies like this will help clinicians move beyond the use of race as a surrogate for genotype. |
format | Online Article Text |
id | pubmed-10104131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-101041312023-04-15 Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension Powell, Nicholas R. Shugg, Tyler Leighty, Jacob Martin, Matthew Kreutz, Rolf P. Eadon, Michael T. Lai, Dongbing Lu, Tao Skaar, Todd C. bioRxiv Article Hypertension (HTN) involves genetic variability in the renin-angiotensin system and characterizing this variability will help advance precision antihypertensive treatments. We previously reported that angiotensinogen (AGT) mRNA is endogenously bound by mir-122-5p and that rs699 A>G significantly decreases reporter mRNA in the functional mirSNP assay PASSPORT-seq. The AGT promoter variant rs5051 C>T is in linkage disequilibrium (LD) with rs699 A>G and increases AGT transcription. We hypothesized that the increased AGT by rs5051 C>T counterbalances AGT decrease by rs699 A>G, and when these variants occur independently, would translate to HTN-related phenotypes. The independent effect of each of these variants is understudied due to their LD, therefore, we used in silico, in vitro, in vivo, and retrospective clinical and biobank analyses to assess HTN and AGT expression phenotypes where rs699 A>G occurs independently from rs5051 C>T. In silico, rs699 A>G is predicted to increase mir-122-5p binding strength by 3%. Mir-eCLIP assay results show that rs699 is 40-45 nucleotides from the strongest microRNA binding site in the AGT mRNA. Unexpectedly, rs699 A>G increases AGT mRNA in a plasmid cDNA HepG2 expression model. GTEx and UK Biobank analyses demonstrate that liver AGT expression and HTN phenotypes were not different when rs699 A>G occurs independently from rs5051 C>T, allowing us to reject the original hypothesis. However, both GTEx and our in vitro experiments suggest rs699 A>G confers cell-type specific effects on AGT mRNA abundance. We found that rs5051 C>T and rs699 A>G significantly associate with systolic blood pressure in Black participants in the UK Biobank, demonstrating a 4-fold larger effect than in White participants. Further studies are warranted to determine if the altered antihypertensive response in Black individuals might be due to rs5051 C>T or rs699 A>G. Studies like this will help clinicians move beyond the use of race as a surrogate for genotype. Cold Spring Harbor Laboratory 2023-04-08 /pmc/articles/PMC10104131/ /pubmed/37066278 http://dx.doi.org/10.1101/2023.04.07.536073 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Powell, Nicholas R. Shugg, Tyler Leighty, Jacob Martin, Matthew Kreutz, Rolf P. Eadon, Michael T. Lai, Dongbing Lu, Tao Skaar, Todd C. Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title | Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title_full | Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title_fullStr | Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title_full_unstemmed | Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title_short | Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension |
title_sort | analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104131/ https://www.ncbi.nlm.nih.gov/pubmed/37066278 http://dx.doi.org/10.1101/2023.04.07.536073 |
work_keys_str_mv | AT powellnicholasr analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT shuggtyler analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT leightyjacob analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT martinmatthew analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT kreutzrolfp analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT eadonmichaelt analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT laidongbing analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT lutao analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension AT skaartoddc analysisofthecombinedeffectofrs699andrs5051onangiotensinogenexpressionandhypertension |